����ӰԺ

The Serum Amyloid A (SAA) Assay* from Siemens Healthineers provides:

• High specificity based on monoclonal antibodies
• Fully automated testing for improved workflow
• A broad initial measuring range (3–200 mg/L) that helps reduce the need for redilutions and supports economical reagent use
• A complete kit, including reagent, calibrator, controls, and supplementary reagent (SCS Cleaner reagent available separately)
• The ability to perform parallel determination of SAA and CRP, which can enhance diagnostic sensitivity for infections ²

High sensitivity in diagnosis and monitoring of inflammatory processes.

Serum amyloid A (SAA) represents a protein family and is an acute-phase protein mainly produced by the liver in response to proinflammatory cytokines secreted by the activated monocytes/macrophage lineages.

Like C-reactive protein (CRP), SAA determination can be used in the diagnosis and monitoring of inflammatory and infectious processes. In contrast to CRP, SAA levels show a stronger response to viral infections, while CRP responds more strongly to systemic bacterial infections.²

SAA plasma levels can increase up to 1000-fold, for instance, due to the effect of IL-6 in the course of a cytokine storm. First elevations are seen 3–6 hours after an inflammatory stimulus, reaching a peak concentration in 2–3 days.^2,6

Mo et al. studied 118 patients with COVID‐19 (102 mild, 16 severe) for the prognostic value of the inflammation markers SAA, CRP, and PCT applying receiver operating characteristic (ROC) curve analysis, a mathematical procedure to determine the predictive value of the cutoff for a test.³

SAA clearly had the highest predictive value for disease progression of the three inflammation markers (AUC = 0.968).

Figure 1. The diagnostic value of inflammatory indicators in predicting acute aggravation of COVID‐19 (orange: SAA, grey: CRP, teal: PCT).³

SAA, as currently understood, is one of the strongest indicators of SARS-CoV-2 inflammation compared to other acute-phase proteins.